Switching from Naltrexone to Acamprosate for Alcohol Use Disorder with Significant Nausea

Rationale for Switching to Acamprosate

Acamprosate is the only intervention with sufficient evidence to conclude it is better than placebo in supporting detoxified, alcohol-dependent patients to maintain abstinence for up to 12 months in primary care settings 1
Acamprosate has been shown to decrease the rate of relapse, maintain abstinence, and decrease severity of relapse when it occurs in detoxified alcoholics 2
Network meta-analysis data shows acamprosate is associated with reduced dropouts compared to placebo (odds ratio 0.73, 95% confidence interval 0.62 to 0.86) 3
Unlike naltrexone, acamprosate is not metabolized by the liver, making it suitable for patients with alcoholic liver disease, which is a common comorbidity in alcohol use disorder 2

Acamprosate should be initiated 3-7 days after the last alcohol consumption and only after withdrawal symptoms have resolved 2
The typical treatment period is 3-6 months, but can extend up to 12 months 2
For patients weighing less than 60 kg, the dose should be decreased by one-third 2
Acamprosate should be used as part of a comprehensive psychosocial treatment program 2

Acamprosate has been shown to increase abstinence rates compared to placebo (odds ratio 1.86, 95% confidence interval 1.49 to 2.33) 3
Acamprosate modulates N-methyl-D-aspartic acid (NMDA) receptor transmission 2

Consider topiramate, which has shown efficacy in reducing heavy drinking and has been associated with decreased liver enzyme levels 4, 5
Baclofen may be considered, particularly in patients with significant liver disease 5

Starting acamprosate too early (immediately after sobering up) may reduce its efficacy since it works best for maintaining abstinence rather than inducing it 2
Failing to combine acamprosate with psychosocial support reduces overall effectiveness 2
Discontinuing treatment prematurely (before 3-6 months) may lead to suboptimal outcomes 2